STOCK TITAN

CymaBay Therapeutics to Report Second Quarter of 2022 Financial Results on Thursday, August 11, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) has announced a conference call scheduled for August 11, 2022, at 4:30 p.m. ET, to discuss its Q2 2022 financial results and provide a business update. The company focuses on therapies for liver diseases and has received breakthrough therapy designation and orphan drug status for its treatment, seladelpar, targeting primary biliary cholangitis (PBC). Investors can access the call by dialing the provided numbers or through the company's website's Investor section.

Positive
  • Received breakthrough therapy designation for seladelpar.
  • Orphan drug status granted for seladelpar in the U.S. and Europe.
Negative
  • None.

NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, August 11, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2022 and to provide a business update.

Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID#13730902. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.

About CymaBay

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), PRIority MEdicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit www.cymabay.com and follow us on Twitter and Linkedin.

Public Relations Contact:            

Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com

Investor Relations Contact:

Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com


FAQ

What is the date and time of CymaBay's Q2 2022 financial results conference call?

The conference call is scheduled for August 11, 2022, at 4:30 p.m. Eastern Time.

How can I access the CymaBay conference call?

You can access the call by dialing 877-407-0784 (U.S. and Canada) or 201-689-8560 (internationally) using Conference ID#13730902, or through the company's Investor section on their website.

What is seladelpar and its significance to CymaBay?

Seladelpar is a first-in-class treatment for primary biliary cholangitis (PBC) and has received breakthrough therapy designation and orphan drug status.

CymaBay Therapeutics, Inc.

NASDAQ:CBAY

CBAY Rankings

CBAY Latest News

CBAY Stock Data

3.73B
110.08M
0.52%
103.13%
5.1%
Biotechnology
Healthcare
Link
United States
Fremont